These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23251855)

  • 1. Hypothermia secondary to ziprasidone use in a man with schizophrenia.
    Sethi R; Kavuru B
    Prim Care Companion CNS Disord; 2012; 14(4):. PubMed ID: 23251855
    [No Abstract]   [Full Text] [Related]  

  • 2. Profound hypothermia secondary to normal ziprasidone use.
    Gibbons GM; Wein DA; Paula R
    Am J Emerg Med; 2008 Jul; 26(6):737.e1-2. PubMed ID: 18606348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.
    Ou JJ; Xu Y; Chen HH; Fan X; Gao K; Wang J; Guo XF; Wu RR; Zhao JP
    Psychopharmacology (Berl); 2013 Feb; 225(3):627-35. PubMed ID: 22926006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
    Kudla D; Lambert M; Domin S; Kasper S; Naber D
    Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).
    Strom BL; Eng SM; Faich G; Reynolds RF; D'Agostino RB; Ruskin J; Kane JM
    Am J Psychiatry; 2011 Feb; 168(2):193-201. PubMed ID: 21041245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia.
    Zhang H; Wang G; Zhao J; Xie S; Xu X; Shi J; Deng H; Li K; Gao C; Wang X; Vanderburg D; Pan S; Tang H; Shu L; Karayal ON
    J Clin Psychopharmacol; 2013 Apr; 33(2):178-85. PubMed ID: 23422376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.
    Arato M; O'Connor R; Meltzer HY;
    Int Clin Psychopharmacol; 2002 Sep; 17(5):207-15. PubMed ID: 12177583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
    Stimmel GL; Gutierrez MA; Lee V
    Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML
    Cochrane Database Syst Rev; 2000; (4):CD001945. PubMed ID: 11034737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
    Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
    Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
    Li YM; Zhao JP; Ou JJ; Wu RR
    Pharmacopsychiatry; 2012 Jul; 45(5):177-81. PubMed ID: 22290206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
    Bogers JPAM; Schulte PFJ; Broekman TG; Moleman P; de Haan L
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1024-1034. PubMed ID: 30025751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.
    Stip E; Cherbal A; Luck D; Zhornitsky S; Bentaleb LA; Lungu O
    Psychopharmacology (Berl); 2017 Apr; 234(7):1045-1058. PubMed ID: 28210783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
    Zhang Y; Dai G
    Hum Psychopharmacol; 2012 Nov; 27(6):605-14. PubMed ID: 24446539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.